Genetic regulation of osteoclast development and function
暂无分享,去创建一个
[1] M. Zaidi,et al. Cathepsin K, Osteoclastic Resorption, and Osteoporosis Therapy , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] A. Zallone,et al. c-Fms and the αvβ3 integrin collaborate during osteoclast differentiation , 2003 .
[3] G. Gronowicz,et al. Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. , 1998, Endocrinology.
[4] S. Mckercher,et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1 , 1997, Nature.
[5] G. Krystal,et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. , 1998, Genes & development.
[6] E. C. Weir,et al. A Role for Cell-Surface CSF-1 in Osteoblast-mediated Osteoclastogenesis , 2002, Calcified Tissue International.
[7] A. Ferré-D’Amaré,et al. Molecular basis of mouse microphthalmia (mi) mutations helps explain their developmental and phenotypic consequences , 1994, Nature Genetics.
[8] C. Remé,et al. Fra-1 replaces c-Fos-dependent functions in mice. , 2000, Genes & development.
[9] M. Gentile,et al. M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss. , 2000, The Journal of clinical investigation.
[10] D. Bowtell,et al. The Cbl protooncoprotein stimulates CSF‐1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation , 1999, The EMBO journal.
[11] Matthew J. Silva,et al. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts , 2002, Nature Network Boston.
[12] H. Okamura,et al. Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. , 1997 .
[13] Hiroshi Takayanagi,et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.
[14] B. Aggarwal,et al. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. , 1999, The Journal of biological chemistry.
[15] S. Nishikawa,et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene , 1990, Nature.
[16] K. Ravichandran,et al. Regulation of the immune response by SHIP. , 2002, Seminars in immunology.
[17] R. Rizzoli,et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. , 1997, The Journal of clinical investigation.
[18] S. Teitelbaum,et al. Bone resorption by osteoclasts. , 2000, Science.
[19] K. J. Moore. Insight into the microphthalmia gene. , 1995, Trends in genetics : TIG.
[20] G. Rodan,et al. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase. , 1998, The Journal of clinical investigation.
[21] T. Martin,et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[22] T. Takeya,et al. Large Scale Gene Expression Analysis of Osteoclastogenesisin Vitro and Elucidation of NFAT2 as a Key Regulator* , 2002, The Journal of Biological Chemistry.
[23] S. Ralston,et al. Paget's Disease of Bone: Evidence for a Susceptibility Locus on Chromosome 18q and for Genetic Heterogeneity , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[24] F. Ross,et al. Estrogen Deficiency Increases the Ability of Stromal Cells to Support Murine Osteoclastogenesis via an Interleukin-1and Tumor Necrosis Factor-mediated Stimulation of Macrophage Colony-stimulating Factor Production* , 1996, The Journal of Biological Chemistry.
[25] R. Hynes,et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. , 2000, The Journal of clinical investigation.
[26] R. Pacifici,et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. , 2000, The Journal of clinical investigation.
[27] D. Veber,et al. Human Osteoclast Cathepsin K Is Processed Intracellularly Prior to Attachment and Bone Resorption , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[28] B. Gelb,et al. Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency , 1996, Science.
[29] N. Copeland,et al. Mild osteopetrosis in the microphthalmia-oak ridge mouse. A model for intermediate autosomal recessive osteopetrosis in humans. , 1995, The American journal of pathology.
[30] D. G. Walker. Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells , 1975, Science.
[31] S. Marks,et al. Bone metabolism in the osteopetrotic rat mutation microphthalmia blanc. , 1995, Bone.
[32] Hiroshi Takayanagi,et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ , 2000, Nature.
[33] G. Rodan,et al. Inhibition of Osteoclast Function by Adenovirus Expressing Antisense Protein-tyrosine Kinase 2* , 2001, The Journal of Biological Chemistry.
[34] Yuqiong Liang,et al. Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification , 1999, Nature Genetics.
[35] E. Wagner,et al. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms , 2002, Journal of Cell Science.
[36] Michael C. Ostrowski,et al. The Microphthalmia Transcription Factor Regulates Expression of the Tartrate‐Resistant Acid Phosphatase Gene During Terminal Differentiation of Osteoclasts , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[37] D. Ory,et al. A Glanzmann’s mutation in β3 integrin specifically impairs osteoclast function , 2001 .
[38] S. Morony,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.
[39] E. Jimi,et al. Activation of NF-κB Is Involved in the Survival of Osteoclasts Promoted by Interleukin-1* , 1998, The Journal of Biological Chemistry.
[40] E. Puscheck,et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[41] B. Aggarwal,et al. Activation of NF-κB by RANK Requires Tumor Necrosis Factor Receptor-associated Factor (TRAF) 6 and NF-κB-inducing Kinase , 1999, The Journal of Biological Chemistry.
[42] W. Dougall,et al. A RANK/TRAF6-dependent Signal Transduction Pathway Is Essential for Osteoclast Cytoskeletal Organization and Resorptive Function* , 2002, The Journal of Biological Chemistry.
[43] R. Wallace,et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis , 2000, Nature Genetics.
[44] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[45] H. Broxmeyer,et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. , 1992, Science.
[46] F. Ross. Interleukin 7 and estrogen-induced bone loss , 2003, Trends in Endocrinology & Metabolism.
[47] Kozo Nakamura,et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β , 2002, Nature.
[48] R. Baron,et al. Src-catalyzed Phosphorylation of c-Cbl Leads to the Interdependent Ubiquitination of Both Proteins* , 2001, The Journal of Biological Chemistry.
[49] S. Takeshita,et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. , 2000, The Journal of clinical investigation.
[50] P. Schlesinger,et al. Characterization of the Osteoclast Ruffled Border Chloride Channel and Its Role in Bone Resorption* , 1997, The Journal of Biological Chemistry.
[51] A. Yamaguchi,et al. Osteoclasts are present in gp130-deficient mice. , 1997, Endocrinology.
[52] B. Gelb,et al. Determination of Bone Markers in Pycnodysostosis: Effects of Cathepsin K Deficiency on Bone Matrix Degradation , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[53] O. Jaillon,et al. The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. , 2000, Bone.
[54] S. Teitelbaum,et al. Osteoclastic bone resorption by a polarized vacuolar proton pump. , 1989, Science.
[55] M A Horton,et al. A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. , 1997, The Journal of clinical investigation.
[56] D. Hewett‐Emmett,et al. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[57] S. Morony,et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.
[58] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[59] E. Stanley,et al. CSF‐1 stimulated multiubiquitination of the CSF‐1 receptor and of Cbl follows their tyrosine phosphorylation and association with other signaling proteins , 1999, Journal of cellular biochemistry.
[60] G. Krystal,et al. Cloning and characterization of human SHIP, the 145-kD inositol 5-phosphatase that associates with SHC after cytokine stimulation. , 1996, Blood.
[61] Shi Wei,et al. Interleukin-4 Reversibly Inhibits Osteoclastogenesis via Inhibition of NF-κB and Mitogen-activated Protein Kinase Signaling* , 2002, The Journal of Biological Chemistry.
[62] M. Podgornik,et al. Osteoprotegerin deficiency and juvenile Paget's disease. , 2002, The New England journal of medicine.
[63] I. Reid,et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. , 2002, Human molecular genetics.
[64] Allan Bradley,et al. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.
[65] P. Jurdic,et al. Podosomes in osteoclast-like cells: structural analysis and cooperative roles of paxillin, proline-rich tyrosine kinase 2 (Pyk2) and integrin αVβ3 , 2001 .
[66] D. Bowtell,et al. Cbl Associates with Pyk2 and Src to Regulate Src Kinase Activity, αvβ3 Integrin-Mediated Signaling, Cell Adhesion, and Osteoclast Motility , 2001, The Journal of cell biology.
[67] Kozo Nakamura,et al. Reciprocal Role of ERK and Nf-κb Pathways in Survival and Activation of Osteoclasts , 2000, The Journal of cell biology.
[68] S. Nishikawa,et al. Vascular Endothelial Growth Factor Can Substitute for Macrophage Colony-Stimulating Factor in the Support of Osteoclastic Bone Resorption , 1999, The Journal of experimental medicine.
[69] M. Whyte,et al. Expansile Skeletal Hyperphosphatasia Is Caused by a 15‐Base Pair Tandem Duplication in TNFRSF11A Encoding RANK and Is Allelic to Familial Expansile Osteolysis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[70] D. Lucas,et al. Structure, function, and biology of SHIP proteins. , 2000, Genes & development.
[71] D. G. Walker. Spleen cells transmit osteopetrosis in mice , 1975, Science.
[72] Y. Ru,et al. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. , 2002, Bone.
[73] R. Russell,et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. , 2002, Blood.
[74] A. Zallone,et al. Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by β3 integrin , 2003, The Journal of cell biology.
[75] Michael C. Ostrowski,et al. Genetic and Physical Interactions betweenMicrophthalmia Transcription Factor and PU.1 Are Necessary for Osteoclast Gene Expression and Differentiation* , 2001, The Journal of Biological Chemistry.
[76] T. Suda,et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. , 2001, Blood.
[77] A. Schulz,et al. Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. , 2000, Human molecular genetics.
[78] J. Clohisy,et al. TAT Fusion Proteins Containing Tyrosine 42-deleted IκBα Arrest Osteoclastogenesis* , 2001, The Journal of Biological Chemistry.
[79] L. Hocking,et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. , 2002, Human molecular genetics.
[80] L. Avioli,et al. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[81] M. W. Wooten,et al. Association of the Atypical Protein Kinase C-interacting Protein p62/ZIP with Nerve Growth Factor Receptor TrkA Regulates Receptor Trafficking and Erk5 Signaling* , 2003, The Journal of Biological Chemistry.
[82] G. Passeri,et al. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. , 1993, Endocrinology.
[83] K. Ozono,et al. Novel mutations in the a3 subunit of vacuolar H(+)-adenosine triphosphatase in a Japanese patient with infantile malignant osteopetrosis. , 2002, Bone.
[84] Shi Wei,et al. Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function. , 2002, Endocrinology.
[85] J. P. Scherft,et al. Fusion disability of embryonic osteoclast precursor cells and macrophages in the microphthalmic osteopetrotic mouse. , 1985, Bone.
[86] H. Okamura,et al. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. , 1998, The Journal of clinical investigation.
[87] P. Delmas,et al. The Collagenolytic Activity of Cathepsin K Is Unique among Mammalian Proteinases* , 1998, The Journal of Biological Chemistry.
[88] F. Ross,et al. RANKing the importance of measles virus in Paget's disease. , 2000, The Journal of clinical investigation.
[89] S. Teitelbaum,et al. Successful bone-marrow transplantation for infantile malignant osteopetrosis. , 1980, The New England journal of medicine.
[90] R. Baron,et al. Colony-stimulating factor-1 induces cytoskeletal reorganization and c-src-dependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts. , 1997, The Journal of clinical investigation.
[91] J. Eisman,et al. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. , 2001, The Journal of endocrinology.
[92] L. Hofbauer,et al. Osteoprotegerin deficiency and juvenile Paget's disease. , 2002, The New England journal of medicine.
[93] Sridhar Ramaswamy,et al. Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability , 2002, Cell.
[94] P. Schlesinger,et al. Substrate Recognition by Osteoclast Precursors Induces C-src/Microtubule Association , 1997, Journal of Cell Biology.
[95] S. Mckercher,et al. Commitment to the monocytic lineage occurs in the absence of the transcription factor PU.1. , 1999, Blood.
[96] D. Lacey,et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. , 2003, The Journal of clinical investigation.
[97] Ulrich Siebenlist,et al. Requirement for NF-κB in osteoclast and B-cell development , 1997 .
[98] Jacques P. Brown,et al. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. , 2002, American journal of human genetics.
[99] W. Dougall,et al. The Involvement of Multiple Tumor Necrosis Factor Receptor (TNFR)-associated Factors in the Signaling Mechanisms of Receptor Activator of NF-κB, a Member of the TNFR Superfamily* , 1998, The Journal of Biological Chemistry.
[100] T. Yoneda,et al. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. , 1992, The Journal of clinical investigation.
[101] L. Notarangelo,et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis , 2000, Nature Genetics.
[102] D. Fisher,et al. Age-resolving Osteopetrosis: A Rat Model Implicating Microphthalmia and the Related Transcription Factor TFE3 , 1998, The Journal of experimental medicine.
[103] A. Grey,et al. Evidence for a functional association between phosphatidylinositol 3-kinase and c-src in the spreading response of osteoclasts to colony-stimulating factor-1. , 2000, Endocrinology.
[104] R. Dubose,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.
[105] Sakae Tanaka,et al. Severe osteopetrosis, defective interleukin‐1 signalling and lymph node organogenesis in TRAF6‐deficient mice , 1999, Genes to cells : devoted to molecular & cellular mechanisms.
[106] T. Martin,et al. IL-12 Alone and in Synergy with IL-18 Inhibits Osteoclast Formation In Vitro1 , 2001, The Journal of Immunology.
[107] E. Wagner,et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. , 1994, Science.
[108] H. Varmus,et al. Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. , 1997, Genes & development.
[109] M. Diaz-Meco,et al. The atypical protein kinase Cs , 2000, EMBO reports.
[110] J. Aubin. Perspectives: Osteoclast adhesion and resorption: The role of podosomes , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[111] S. Morony,et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.
[112] Michael C. Ostrowski,et al. TFEC is a macrophage-restricted member of the microphthalmia-TFE subfamily of basic helix-loop-helix leucine zipper transcription factors. , 1999, Journal of immunology.
[113] H. Okamura,et al. Interleukin-18 (Interferon-γ–inducing Factor) Is Produced by Osteoblasts and Acts Via Granulocyte/Macrophage Colony-stimulating Factor and Not Via Interferon-γ to Inhibit Osteoclast Formation , 1997, The Journal of experimental medicine.
[114] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[115] D L Lacey,et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[116] R. Pacifici,et al. Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[117] Y. Oike,et al. Granulocyte/macrophage colony-stimulating factor and interleukin-3 correct osteopetrosis in mice with osteopetrosis mutation. , 1999, The American journal of pathology.
[118] A. Schulz,et al. Loss of the ClC-7 Chloride Channel Leads to Osteopetrosis in Mice and Man , 2001, Cell.
[119] B. Riggs,et al. Estrogen and the Male Skeleton , 2002 .
[120] D. Fisher,et al. Linking osteopetrosis and pycnodysostosis: Regulation of cathepsin K expression by the microphthalmia transcription factor family , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[121] D. Lacey,et al. The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts , 1999, The Journal of cell biology.
[122] Hao Wu,et al. Distinct molecular mechanism for initiating TRAF6 signalling , 2002, Nature.
[123] X. Xie,et al. Isolation and reconstitution of a vacuolar-type proton pump of osteoclast membranes. , 1994, The Journal of biological chemistry.
[124] Sheila J. Jones,et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[125] E. Wagner,et al. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation , 2000, Nature Genetics.
[126] D. Hewett‐Emmett,et al. Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. , 1985, The New England journal of medicine.
[127] G. Roodman,et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. , 2001, The Journal of clinical investigation.